Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
|
praluzatamab ravtansine (CX-2009) • pacmilimab (CX-072)